IRIS
Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.536
NA - Nord America 6.531
SA - Sud America 1.656
EU - Europa 1.090
Continente sconosciuto - Info sul continente non disponibili 402
AF - Africa 160
OC - Oceania 15
AN - Antartide 1
Totale 17.391
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.272
SG - Singapore 4.885
BR - Brasile 1.361
CN - Cina 1.020
VN - Vietnam 785
IT - Italia 456
HK - Hong Kong 260
AR - Argentina 119
CA - Canada 111
GB - Regno Unito 109
IN - India 92
BD - Bangladesh 91
MX - Messico 90
DE - Germania 86
FR - Francia 82
ZA - Sudafrica 63
IQ - Iraq 57
EC - Ecuador 51
ID - Indonesia 43
PL - Polonia 42
RU - Federazione Russa 39
ES - Italia 38
JP - Giappone 37
NL - Olanda 35
TR - Turchia 31
UA - Ucraina 28
PK - Pakistan 27
FI - Finlandia 25
CO - Colombia 23
MY - Malesia 23
VE - Venezuela 23
SE - Svezia 22
PY - Paraguay 21
MA - Marocco 20
UY - Uruguay 19
CL - Cile 18
UZ - Uzbekistan 18
AE - Emirati Arabi Uniti 17
EG - Egitto 17
CZ - Repubblica Ceca 16
DZ - Algeria 16
NP - Nepal 16
PH - Filippine 16
SA - Arabia Saudita 16
KE - Kenya 15
LT - Lituania 15
JM - Giamaica 14
IE - Irlanda 12
JO - Giordania 12
TN - Tunisia 12
AU - Australia 11
CR - Costa Rica 11
AT - Austria 10
BO - Bolivia 10
KZ - Kazakistan 10
AL - Albania 9
PE - Perù 9
PS - Palestinian Territory 9
CH - Svizzera 8
OM - Oman 8
IL - Israele 7
KR - Corea 7
PT - Portogallo 7
TT - Trinidad e Tobago 7
DO - Repubblica Dominicana 6
AZ - Azerbaigian 5
BE - Belgio 5
GR - Grecia 5
LB - Libano 5
NO - Norvegia 5
RO - Romania 5
TH - Thailandia 5
BA - Bosnia-Erzegovina 4
HN - Honduras 4
IR - Iran 4
KG - Kirghizistan 4
KW - Kuwait 4
NG - Nigeria 4
BH - Bahrain 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
CY - Cipro 3
ET - Etiopia 3
GT - Guatemala 3
HR - Croazia 3
LK - Sri Lanka 3
MD - Moldavia 3
RS - Serbia 3
SI - Slovenia 3
TW - Taiwan 3
BB - Barbados 2
BG - Bulgaria 2
DK - Danimarca 2
EE - Estonia 2
GE - Georgia 2
GY - Guiana 2
HU - Ungheria 2
KH - Cambogia 2
LV - Lettonia 2
MM - Myanmar 2
Totale 16.960
Salva come PNG Salva come JPEG
Città #
Singapore 1.913
San Jose 1.102
Ashburn 1.033
The Dalles 848
Dallas 458
Council Bluffs 427
Shanghai 340
Beijing 318
Ho Chi Minh City 287
Hong Kong 245
Santa Clara 225
Hanoi 171
Milan 133
São Paulo 121
Boardman 110
Los Angeles 108
New York 88
Rome 64
Rio de Janeiro 46
Mexico City 45
Seattle 42
Phoenix 41
Chicago 37
Da Nang 37
Belo Horizonte 36
Johannesburg 34
Warsaw 34
Brooklyn 33
Buffalo 33
Orem 33
Atlanta 31
Tokyo 31
Chandler 30
London 29
Haiphong 28
Brasília 27
Montreal 27
Toronto 25
Charlotte 24
Dhaka 24
Helsinki 23
Curitiba 21
Guayaquil 20
Hải Dương 20
San Francisco 20
Boston 19
Turin 19
Campinas 18
Ribeirão Preto 18
Baghdad 17
Naples 17
Amsterdam 16
Houston 16
Manchester 16
Montevideo 16
Philadelphia 16
Porto Alegre 16
Stockholm 16
Tashkent 15
Wilmington 15
Ankara 14
Assago 14
Bologna 14
Cape Town 14
Denver 14
Goiânia 14
Paris 14
Quito 14
Frankfurt am Main 13
Hillsboro 13
Asunción 12
Chennai 12
Detroit 12
Munich 12
Sorocaba 12
Amman 11
Biên Hòa 11
Buenos Aires 11
Caxias do Sul 11
Dublin 11
Kingston 11
New Delhi 11
Reston 11
Thái Nguyên 11
Bắc Ninh 10
Cairo 10
Kuala Lumpur 10
Lauterbourg 10
Mumbai 10
Recife 10
Salvador 10
San José 10
Aracaju 9
Campo Grande 9
Hangzhou 9
Indaiatuba 9
Jacksonville 9
Joinville 9
Nairobi 9
Poplar 9
Totale 9.521
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study 212
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer 186
Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma 170
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma 145
Morbidity And Complication Of Minimally Invasive Staging For Apparent Early-Stage Epithelial Ovarian Cancer: A Preliminary Analysis Of REMISSION Study 129
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 102
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial 99
Pembrolizumab for locally advanced cervical cancer - Authors' reply 94
Mirvetuximab soravtansine in folate receptor alpha (FRα)–high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial 88
Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer 86
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 83
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey 81
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 81
A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer 78
Accuracy of pre-operative hysteroscopic guided biopsy for predicting final pathology in uterine malignancies 78
Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein 77
3D vision improves outcomes in early cervical cancer treated with laparoscopic type B radical hysterectomy and pelvic lymphadenectomy 73
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 73
Uterine serous carcinoma 72
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 71
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group 71
Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis 71
KEYNOTE-B21: a missed opportunity or a turning point in adjuvant immunotherapy for dMMR endometrial cancer? 70
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study 69
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer 69
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial 68
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer 67
A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses 66
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial 66
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study 65
Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial 65
A Treatment Selection Protocol for Recurrent Ovarian Cancer Patients: The Role of FDG-PET/CT and Staging Laparoscopy 65
Adoptive immunotherapy with cytokine-induced killer cells generated with a new GMP-grade protocol 65
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 65
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) 64
When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer 63
Navigating the Landscape of Resistance Mechanisms in Antibody-Drug Conjugates for Cancer Treatment 63
Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors 62
A critical assessment on the role of sentinel node mapping in endometrial cancer 62
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 62
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis 61
Peritoneal cytology as prognostic factor in cervical cancer 61
[Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer.] 61
Assessing the Risk of Occult Cancer and 30-day Morbidity in Women Undergoing Risk-reducing Surgery: A Prospective Experience. 61
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 61
Is surgical restaging indicated in apparent stage IA pure ovarian dysgerminoma? The MITO group retrospective experience 60
Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 60
Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment 59
Advanced ovarian cancer: Omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor 59
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial 58
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy 58
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study 57
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial 57
A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04) 56
Artificial intelligence estimates the impact of human papillomavirus types in influencing the risk of cervical dysplasia recurrence: progress toward a more personalized approach 55
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib 55
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023* 55
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms 55
Clinical characteristics and molecular aspects of low-grade serous ovarian and peritoneal cancer: a multicenter, observational, retrospective analysis of MITO Group (MITO 22) 55
Trabectedin as a chemotherapy option for patients with BRCA deficiency 55
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 55
Use of Adjuvant Therapy in Patients with FIGO Stage III Endometrial Carcinoma: A Multicenter Retrospective Study 54
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer 54
"Tumori della vulva e della vagina" 54
Nomogram-based prediction of cervical dysplasia persistence/recurrence 54
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial 54
Minimally Invasive Surgical Staging for Ovarian Carcinoma: A Propensity-Matched Comparison With Traditional Open Surgery 54
Celecoxib plus cartioplatin in heavily pre-treated patients with recurrent ovarian carcinoma: Preliminary results of a Phase II study 53
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL) 53
Advances in laparoscopic surgery for cervical cancer 53
Regarding "The Role of Routine Peritoneal and Omental Biopsies at Risk-reducing Salpingo-oophorectomy" 53
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile 53
Photodynamic therapy with M-ALA as non surgical treatment option in patients with primary extramammary Paget's disease 53
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study 53
Advanced vulvar carcinoma: Is it worth operating? A perioperative management protocol for radical and reconstructive surgery 52
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix 52
Human papillomavirus (HPV) persistence and HPV 31 predict the risk of recurrence in high-grade vaginal intraepithelial neoplasia. 52
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer 52
Extraperitoneal Robotic-Assisted Para-Aortic Lymphadenectomy in Gynecologic Cancer Staging: Current Evidence 52
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 52
A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer - A Multicentre Italian Trial in Ovarian cancer (MITO-5) study 51
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer 51
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial 51
Bulky mesonephric adenocarcinoma of the uterine cervix treated with neoadjuvant chemotherapy and radical surgery: report of the first case 51
Sentinel Node Mapping in Endometrial Cancer By Using Hysteroscopic Injection of Indocyanine Green and Laparoscopic Near-Infrared Fluorescence Imaging: A Preliminary Experience 50
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial 50
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial 50
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer 50
TP53 mutations and survival in ovarian carcinoma patients receiving first-line chemotherapy plus bevacizumab: Results of the MITO16A/MaNGO OV-2 study 50
TERAPIA PRIMARIA DEL CARCINOMA DELL'ENDOMETRIO: CHEMIOTERAPIA 50
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance 49
Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS) 49
Surgical Management and Prognostic Factors of Vulvovaginal Melanoma 49
Cost-Effectiveness Analysis of HRD Testing for Previously Treated Patients with Advanced Ovarian Cancer in Italy 49
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer 49
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 49
Survival with Cemiplimab in Recurrent Cervical Cancer 49
A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: A pilot study 49
Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study 49
Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features 48
Totale 6.610
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.697
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.697
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202217 0 0 0 2 0 0 0 2 1 2 4 6
2022/202387 13 2 7 13 2 8 0 11 16 9 5 1
2023/2024907 6 5 11 3 0 8 2 0 271 21 187 393
2024/20254.263 82 108 147 44 17 297 336 248 683 1.105 623 573
2025/202610.773 1.630 779 648 982 378 614 2.940 520 566 730 413 573
2026/20271.316 580 736 0 0 0 0 0 0 0 0 0 0
Totale 17.391